Innoviva (NASDAQ:INVA - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.57 EPS for the quarter, Zacks reports. The firm had revenue of $91.81 million for the quarter. Innoviva had a net margin of 18.31% and a return on equity of 20.84%.
Innoviva Stock Up 2.1 %
NASDAQ:INVA traded up $0.37 on Friday, hitting $17.92. 648,544 shares of the company's stock traded hands, compared to its average volume of 540,793. The company has a current ratio of 1.79, a quick ratio of 1.64 and a debt-to-equity ratio of 0.38. Innoviva has a 1 year low of $14.32 and a 1 year high of $21.28. The firm has a 50-day moving average price of $18.04 and a 200-day moving average price of $18.85. The company has a market cap of $1.12 billion, a PE ratio of 25.97 and a beta of 0.55.
Analyst Upgrades and Downgrades
Separately, StockNews.com downgraded Innoviva from a "buy" rating to a "hold" rating in a report on Saturday, February 22nd.
Check Out Our Latest Report on Innoviva
About Innoviva
(
Get Free Report)
Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Read More
Before you consider Innoviva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innoviva wasn't on the list.
While Innoviva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
